Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

Novo Nordisk lowers full-year profit guidance in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

Novo Nordisk loses further ground in obesity market

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Novo Nordisk Q3 sales in line with forecasts in new CEO's maiden quarter

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...

Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S.

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Ozempic Maker Novo Nordisk Lowers 2025 Outlook After Tepid Results

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Bagsværd, 5 November, 2025 - Financial report for the period 1 January 2025 to 30 September 2025 Operating profit increased ...